These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

532 related items for PubMed ID: 12163389

  • 1. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.
    Poulaki V, Mitsiades CS, Kotoula V, Tseleni-Balafouta S, Ashkenazi A, Koutras DA, Mitsiades N.
    Am J Pathol; 2002 Aug; 161(2):643-54. PubMed ID: 12163389
    [Abstract] [Full Text] [Related]

  • 2. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R, Bedi A.
    Cancer Res; 2002 Aug 01; 62(15):4180-5. PubMed ID: 12154014
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I.
    Cancer Res; 2000 Aug 01; 60(15):4122-9. PubMed ID: 10945619
    [Abstract] [Full Text] [Related]

  • 5. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B.
    Clin Cancer Res; 2001 Dec 01; 7(12):3874-83. PubMed ID: 11751478
    [Abstract] [Full Text] [Related]

  • 6. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP, Zisman A, Bonavida B.
    Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140
    [Abstract] [Full Text] [Related]

  • 7. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.
    Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF.
    Cancer Res; 2004 Oct 01; 64(19):7086-91. PubMed ID: 15466204
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N, Poulaki V, Mitsiades C, Tsokos M.
    Cancer Res; 2001 Mar 15; 61(6):2704-12. PubMed ID: 11289151
    [Abstract] [Full Text] [Related]

  • 10. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein.
    Frese S, Brunner T, Gugger M, Uduehi A, Schmid RA.
    J Thorac Cardiovasc Surg; 2002 Jan 15; 123(1):168-74. PubMed ID: 11782771
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M, Mizuguchi J.
    J Orthop Res; 2003 Sep 15; 21(5):949-57. PubMed ID: 12919886
    [Abstract] [Full Text] [Related]

  • 13. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
    Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC.
    Oncogene; 2002 Aug 22; 21(37):5673-83. PubMed ID: 12173037
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis.
    Kontny HU, Hämmerle K, Klein R, Shayan P, Mackall CL, Niemeyer CM.
    Cell Death Differ; 2001 May 22; 8(5):506-14. PubMed ID: 11423911
    [Abstract] [Full Text] [Related]

  • 17. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.
    Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, Gregor M, Lauer UM, Bitzer M.
    Hepatology; 2006 Mar 22; 43(3):425-34. PubMed ID: 16583461
    [Abstract] [Full Text] [Related]

  • 18. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.
    Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP.
    Blood; 2002 Mar 15; 99(6):2162-71. PubMed ID: 11877293
    [Abstract] [Full Text] [Related]

  • 19. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
    Ng CP, Bonavida B.
    Mol Cancer Ther; 2002 Oct 15; 1(12):1051-8. PubMed ID: 12481428
    [Abstract] [Full Text] [Related]

  • 20. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand.
    Ozoren N, Kim K, Burns TF, Dicker DT, Moscioni AD, El-Deiry WS.
    Cancer Res; 2000 Nov 15; 60(22):6259-65. PubMed ID: 11103780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.